The ChemRar Research Institute, a resident of the Skolkovo Foundation's Biomedical Technologies Cluster, has created a platform for the development of innovative drugs against the new coronavirus infection. The company invites potential partners to use the platform and invites international companies to cooperate in finding solutions for the treatment of COVID-19.
Since the start of the COVID-19 pandemic, ChemRar Research Institute has developed and tested more than ten potentially active antiviral drug candidates. Now the company has expanded its anti-COVID direction and presented a platform for the development of innovative drugs.
The platform ensures the development of a ready-made preclinical candidate from scratch in just a few months. The advantages of the platform are the completeness of the proposed antiviral models and the speed of execution of work due to the library of compounds available on a day to day.
The platform includes:
• Library of potential antiviral molecules (13 thousand compounds)
• CPE testing with SARS-CoV-2 virus
• Protease tests (3CL and PLpro)
• Polymerase tests (RdRp)
• Spike research (ACE2-S1)
• Study of the antiviral activity of a future candidate for hamsters
• Pharmacokinetic studies (ADME, invitro and invivo tests)
• Services for medico-chemical optimization.
Irina Tyrnova, General Director of Research Institute ChemRar: “Our development - a comprehensive platform for the search for small molecules - will allow the global pharmaceutical community to find new approaches to create a cure for the new coronavirus infection. We invite international partners interested in forming a pipeline of innovative antiviral candidates for cooperation.”
Ivan Taskin, project manager of the Skolkovo Foundation's Biomedical Technologies Cluster: “Since the early days of the novel coronavirus infection COVID-19, the Skolkovo Foundation has been actively promoting the development of companies that develop solutions that include the creation of new antiviral drugs, vaccines and diagnostic techniques. In 2020, the Fund developed a procedure for accelerating support for priority projects aimed at combating the spread of COVID-19 and the consequences of the pandemic. Within the framework of this procedure, BMT Cluster selected 10 such projects. Some solutions of residents have already received registration certificates and are actively used in practical healthcare. However, the issue of combating the new virus is quite acute for a number of reasons, including the lack of effective and safe means of prevention and treatment. The platform for the development of innovative drugs created by the Research Institute Chem Rar will be able to help provide the national healthcare with new drugs, while attracting partners from abroad.”
The ChemRar group of companies unites research, production and investment companies in the field of pharmaceuticals for the development and commercialization of innovative pharmaceuticals, diagnostics, prevention and new methods of treatment of life-threatening diseases in Russia and abroad.
Tel .: +7 495 925 30 74 # 520
Skolkovo Foundation is a non-profit organization created in 2010 and acting as the managing company of the Skolkovo Innovation Center. The purpose of the Foundation is to support technological entrepreneurship in Russia and commercialize the results of research activities. The number of Skolkovo residents has already approached 2.5 thousand. The Fund provides them with a range of services necessary to bring developments to the Russian and international markets. Resident status gives the company tax and customs benefits. In 2019, the residents' revenue amounted to more than 100 billion rubles, and the amount of investments attracted by them exceeded 13 billion rubles. Since 2019, the law allows any organization engaged in research activities in Russia to gain access to all the services and benefits of the Innovation Center. The Skolkovo Innovation Center hosts the Skolkovo Institute of Science and Technology (Skoltech), one of the top 100 young universities in the world according to Nature Index. The infrastructure of the Innovation Center is made up, in particular, of the largest Technopark in Europe and research centers of industrial partners. In 2019, three new partner R&D centers were opened in the Innovation Center - Sibur, TMK and Tatneft. On the territory of Skolkovo, a total of more than 750 thousand square meters have already been commissioned. m. residential areas, research and educational centers. Extra-budgetary investments in infrastructure creation exceeded RUB 100 billion.